Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.45 |
| ▸ | WNT1 | P04628 | 8/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 5/20 | 0.43 |
| ▸ | CLK3 | P49761 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137915 | 0.77 | JAK2 (0.57) | GSK3BDYRK1AWNT1JAK2CLK2 | |
| SCHEMBL25934785 | 0.76 | CDK7 (0.44) | DYRK1AJAK2CLK2CLK3 | |
| SCHEMBL24137792 | 0.75 | JAK2 (0.50) | DYRK1AWNT1JAK2CLK2CLK3 | |
| SCHEMBL25935962 | 0.74 | ABL1 (0.45) | GSK3BJAK2 | |
| SCHEMBL21318857 | 0.70 | JAK2 (0.56) | DYRK1AWNT1JAK2CLK2CLK3 | |
| SCHEMBL24137560 | 0.70 | CDK2 (0.57) | GSK3BDYRK1AWNT1JAK2 | |
| SCHEMBL15883302 | 0.69 | DYRK1A (0.54) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL21318652 | 0.69 | JAK2 (0.54) | DYRK1AWNT1JAK2CLK2 | |
| SCHEMBL10213929 | 0.68 | JAK2 (0.81) | DYRK1AJAK2CLK2 | |
| SCHEMBL25936215 | 0.68 | JAK2 (0.50) | DYRK1AWNT1JAK2CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | GSK3B 267/4885DYRK1A 495/4885WNT1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.